1. MaynardJE. Hepatitis B: global importance and need for control. Vaccine1990;8(Suppl):S18. CrossRef

2. DoddRY, NathN. Increased risk for lethal forms of liver disease among HBsAg‐positive blood donors in the United States. J Virol Methods1987;17:81. CrossRef

3. LeeWM. Hepatitis B virus infection. N Engl J Med1997;337:1733. CrossRef

4. HoofnagleJH. Chronic hepatitis B. N Engl J Med1990;323:337. CrossRef

5. McQuillanGM, ColemanPJ, Kruszon‐MoranD, et al.Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health1999;89:14. CrossRef

6. Centers for Disease Control (CDC). Screening for hepatitis B virus infection among refugees arriving in the United States, 1979–1991. MMWR Morb Mortal Wkly Rep1991;40:784.

7. MitchellT, AmstrongGL, HuJL, et al.The increasing burden of imported chronic hepatitis B—United States 1974‐2008. PLos One2011;6:1.

8. KimWR, BensonJT, TherneauTM, et al.Changing epidemiology of hepatitis B in a U.S. community. Hepatology2004;39:811. CrossRef

9. GishRG, GadanoAC. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepatol2006;13:787. CrossRef

10. LyKN, XingJ, KlevensRM, et al.The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Int Med2012;156:271. CrossRef

11. LeeTA, VeenstraDL, IloejeUH, et al.Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol2004;38(10 Suppl):S144. CrossRef

12. TepperM. Acute hepatitis B incidence in Canada. Can Commun Dis Rep1997;23:52.

13. Centers for Disease Control and Prevention (CDC). Hepatitis B vaccination – United States, 1982–2002. MMWR Morb Mortal Wkly Rep2002;51:563.

14. MastEE, MahoneyFJ, AlterMJ, et al.Progress toward elimination of hepatitis B virus transmission in the United States. Vaccine1998;16(Suppl):S48. CrossRef

15. Centers for Disease Control and Prevention (CDC). Incidence of acute hepatitis B – United States, 1990–2002. MMWR Morb Mortal Wkly Rep2004;52:1252.

16. MoyerLA, MastEE. Hepatitis B: virology, epidemiology, disease, and prevention, and an overview of viral hepatitis. Am J Prev Med1994;10(Suppl):45.

17. KaneM. Global programme for control of hepatitis B infection. Vaccine1995;13(Suppl 1):S47. CrossRef

18. McMahonBJ, LanierAP, WainwrightRB. Hepatitis B and hepatocellular carcinoma in Eskimo/Inuit population. Int J Circumpolar Health1998;57(Suppl 1):414.

19. BortolottiF, BertaggiaA, CrivellaroC, et al.Chronic evolution of acute hepatitis type B: prevalence and predictive markers. Infection1986;14:64. CrossRef

20. ChuCM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol2000;15(Suppl):E25. CrossRef

21. de JonghFE, JanssenHL, De ManRA, et al.Survival and prognostic indicators in hepatitis B surface antigen‐positive cirrhosis of the liver. Gastroenterology1992;103:1630.

22. de FranchisR, MeucciG, VecchiM, et al.The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med1993;118:191. CrossRef

23. FattovichG, BrolloL, GiustinaG, et al.Natural history and prognostic factors for chronic hepatitis type B. Gut1991;32:294. CrossRef

24. LokAS. Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis1992;10:46. CrossRef

25. Centers for Disease Control and Prevention (CDC). Recommended childhood immunization schedule – United States, 1999. MMWR Morb Mortal Wkly Rep1999;48:12.

26. HadlerSC. Hepatitis B virus infection and health care workers. Vaccine1990;8(Suppl):S24. CrossRef

27. CassidyW. School‐based adolescent hepatitis B immunization programs in the United States: strategies and successes. Pediatr Infect Dis J1998;17(Suppl):S43. CrossRef

28. DienstagJL. Sexual and perinatal transmission of hepatitis B. Hepatology1997;26(3 Suppl 1):66S. CrossRef

29. AngusPW. Review: hepatitis B and liver transplantation. J Gastroenterol Hepatol1997;12:217. CrossRef

30. ArevaloJA, WashingtonAE. Cost‐effectiveness of prenatal screening and immunization for hepatitis B virus. JAMA1988;259:365. CrossRef

31. GishRG. Clinical trial results of new therapies for HBV: implications for treatment guidelines. Semin Liver Dis2005;25(Suppl 1):29. CrossRef

32. PerraultJ, McGillDB, OttBJ, et al.Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology1978;74:103.

33. YounossiZM, TeranJC, GaniatsTG, et al.Ultrasound‐guided liver biopsy for parenchymal liver disease: an economic analysis. Dig Dis Sci1998;43:46. CrossRef

34. ChenCJ, YangHI, SuJ, et al.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA2006;295:65. CrossRef

35. IkedaK, AraseY, KobayashiM, et al.Hepatitis B virus‐related hepatocellular carcinogenesis and its prevention. Intervirology2005;48:29. CrossRef

36. YuMW, YehSH, ChenPJ, et al.Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst2005;97:265. CrossRef

37. YuenMF, YuanHJ, WongDK, et al.Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut2005;54:1610. CrossRef

38. PitonA, PoynardT, Imbert‐BismutF, et al.Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology1998;27:1213. CrossRef

39. PratiD, TaioliE, ZanellaA, et al.Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med2002;137:1. CrossRef

40. KimHC, NamCM, JeeSH, et al.Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ2004;328:983. CrossRef

41. LokASF, McMahonBJ. AASLD Practice Guidelines. Chronic hepatitis B. Hepatology2009;50:661. CrossRef

42. KnodellRG, IshakKG, BlackWC, et al.Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology1981;1:431. CrossRef

43. HoofnagleJH, Di BisceglieAM. Serologic diagnosis of acute and chronic viral hepatitis. Semin Liver Dis1991;11:73. CrossRef

44. ChauKH, HargieMP, DeckerRH, et al.Serodiagnosis of recent hepatitis B infection by IgM class anti‐HBc. Hepatology1983;3:142. CrossRef

45. KanekoS, KobayashiK, MillerRH. Detection of hepatitis B virus DNA using the polymerase chain reaction technique. J Clin Lab Anal1990;4:479. CrossRef

46. KoYC, ChungDC. Transmission of hepatitis B virus infection by iatrogenic intramuscular injections in an endemic area. Gaoxiong Yi Xue Ke Xue Za Zhi1991;7:313.

47. Avon. Risks to surgeons and patients from HIV and hepatitis: guidelines on precautions and management of exposure to blood or body fluids. Joint Working Party of the Hospital Infection Society and the Surgical Infection Study Group. BMJ1992;305:1337. CrossRef

48. California Department of Health Services. Guidelines for preventing the transmission of bloodborne pathogens in health care settings, issued. Calif Nurse1993;89:9.

49. PetrosilloN, PuroV, JaggerJ, et al.The risks of occupational exposure and infection by human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in the dialysis setting. Italian Multicenter Study on Nosocomial and Occupational Risk of Infections in Dialysis. Am J Infect Control1995;23:278. CrossRef

50. Centers for Disease Control and Prevention (CDC). Updated CDC recommendations for the management of hepatitis B virus‐infected health‐care providers and students. MMWR Morb Mortal Wkly Rep2012;61(RR–3):1.

51. PalmovicD, Crnjakovic‐PalmovicJ. Prevention of hepatitis B virus (HBV) infection in health‐care workers after accidental exposure: a comparison of two prophylactic schedules. Infection1993;21:42. CrossRef

52. CraxiA, TineF, VinciM, et al.Transmission of hepatitis B and hepatitis delta viruses in the households of chronic hepatitis B surface antigen carriers: a regression analysis of indicators of risk. Am J Epidemiol1991;134:641.

53. KashiwagiS, HayashiJ, IkematsuH, et al.Transmission of hepatitis B virus among siblings. Am J Epidemiol1984;120:617.

54. CrisseyJT. Bedbugs: An old problem with a new dimension. Int J Dermatol1981;20:411. CrossRef

55. Japanese Red Cross NAT Screening Research Group. Nationwide nucleic acid amplification testing of hepatitis B virus, hepatitis C virus and human immunodeficiency virus type 1 for blood transfusion and follow‐up study of nucleic acid amplification positive donors. Japanese Red Cross NAT Screening Research Group. Jpn J Infect Dis2000;53:116.

56. AllainJP. Genomic screening for blood‐borne viruses in transfusion settings. Clin Lab Haematol2000;22:1. CrossRef

57. KoppelmanMH, AssalA, ChudyM, et al.Multicenter performance evaluation of a transcription‐mediated amplification assay for screening of human immunodeficiency virus‐1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations. Transfusion2005;45:1258. CrossRef

58. Anon. Infectious disease testing for blood transfusions. NIH Consensus Development Panel on Infectious Disease Testing for Blood Transfusions. JAMA1995;274:1374. CrossRef

59. Anon. Expanded programme on immunization. Global Advisory Group – Part II. Achieving the major disease control goals. Wkly Epidemiol Rec1994;69:29.

60. AlbertiA, PontissoP, ChemelloL, et al.The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol1995;22(1 Suppl):38.

61. RizzettoM, CiancioA. Epidemiology of hepatitis D. Semin Liver Dis2012;32:211. CrossRef

62. GhendonY. WHO strategy for the global elimination of new cases of hepatitis B. Vaccine1990;8(Suppl):S129. CrossRef

63. HallauerJ. VHPB: summary of strategies and recommendations. Viral Hepatitis Prevention Board. Vaccine1995;13(Suppl 1):S61. CrossRef

64. SafaryA, BeckJ. Vaccination against hepatitis B: current challenges for Asian countries and future directions. J Gastroenterol Hepatol2000;15:396. CrossRef

65. ChangMH, ChenCJ, LaiMS, et al.Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med1997;336:1855. CrossRef

66. ChangMH. Hepatitis B: long‐term outcome and benefits from mass vaccination in children. Acta Gastroenterol Belg1998;61:210.

67. ACOG educational bulletin. Viral hepatitis in pregnancy. Number 248, July 1998 (replaces No. 174, November 1992). American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet1998;63:195. CrossRef

68. SpradlingPR, XingJ, WilliamsR, et al.Immunity to hepatitis B virus (HBV) infection two decades after implementation of universal infant HBV vaccination: associated of detectable residual antibodies and response to a single HBV challenge dose. Clin Vaccine Immunol2013;4:559. CrossRef

69. CooksleyWG. What did we learn from the Shanghai hepatitis A epidemic?J Viral Hepatol2000;7(Suppl 1):1. CrossRef

70. LokAS, HeathcoteEJ, HoofnagleJH. Management of hepatitis B: 2000 – summary of a workshop. Gastroenterology2001;120:1828. CrossRef

71. StevensCE, ToyPT, TaylorPE, et al.Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long‐term protection. Pediatrics1992;90:170.

72. WuJS, HwangLY, GoodmanKJ, et al.Hepatitis B vaccination in high‐risk infants: 10‐year follow‐up. J Infect Dis1999;179:1319. CrossRef

73. McMahonBJ, BrudenDA, PetersonKM, et al.Immunogenicity and duration of protection of hepatitis B vaccine: results of a 15‐year follow‐up. Hepatology2000;32:379A. CrossRef

74. ShawFEJr, GrahamDJ, GuessHA, et al.Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years. Am J Epidemiol1988;127:337.

75. HalseyNA, DuclosP, Van DammeP, et al.Hepatitis B vaccine and central nervous system demyelinating diseases. Viral Hepatitis Prevention Board. Pediatr Infect Dis J1999;18:23. CrossRef

76. Anon. Expanded Programme on Immunization (EPI) Lack of evidence that hepatitis B vaccine causes multiple sclerosis. Wkly Epidemiol Rec1997;72:149.

77. ChanHL, HuiAY, WongML, et al.Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut2004;53:1494. CrossRef

78. ChuCM, LinCC, ChenYC, et al.Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B infection. Br J Cancer2012;107:2010. CrossRef

79. SonneveldMJ, RijckborstV, ZeuzemS, et al.Presence of precore and core promoter mutatnts limits the probability of response to peginterferon in hepatitis B e antigen‐positive chronic hepatitis B. Hepatology2012;56:67. CrossRef

80. YangHC, ChenCL, ShenYC, et al.Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon‐induced hepatitis B e antigen seroconversion. Hepatology2013;57:934. CrossRef

81. FanW, ShiB, WeiH, et al.Comparison of hepatitis B X gene mutation between patients with hepatocellular carcinoma and patients with chronic hepatitis B. Virus Genes2011;42:162. CrossRef

82. TiollaisP, PourcelC, DejeanA. The hepatitis B virus. Nature1985;317:489. CrossRef

83. CarmanWF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepatol1997;4(Suppl 1):11. CrossRef

84. CarmanWF, ZanettiAR, KarayiannisP, et al.Vaccine‐induced escape mutant of hepatitis B virus. Lancet1990;336:325. CrossRef

85. HsuHY, ChangMH, NiYH, et al.Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology1997;26:786. CrossRef

86. LaiMW, LinTY, TsaoKC, et al.Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination. Gastroenterology2012;143:400. CrossRef

87. LacombeK, BoydA, LavocatF, et al.High incidence of treatment‐induced and vaccine‐escape hepatitis B virus mutants among HIV‐hepatitis B infected patients. Hepatology2013;58:912. CrossRef

88. ShawT, LocarniniSA. Preclinical aspects of lamivudine and famciclovir against hepatitis B virus. J Viral Hepatol1999;6:89. CrossRef

89. HarpazR, Von SeidleinL, AverhoffFM, et al.Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. NEJM1996;334:549. CrossRef

90. WrightTL, LauJY. Clinical aspects of hepatitis B virus infection. Lancet1993;342:1340. CrossRef

91. ChanG, KowdleyKV. Extrahepatic manifestations of chronic viral hepatitis. Compr Ther1995;21:200.

92. GuillevinL, LhoteF, JarrousseB, et al.Polyarteritis nodosa related to hepatitis B virus. A retrospective study of 66 patients. Ann Med Interne (Paris)1992;143(Suppl 1):63.

93. ShermanM, KleinA. AASLD single‐topic research conference on hepatocellular carcinoma: conference proceedings. Hepatology2004;40:1465. CrossRef

94. KewMC. Epidemiology of hepatocellular carcinoma and its viral risk factors. Acta Gastroenterol Belg2000;63:227.

95. MilichDR, JonesJ, HughesJ, et al.Hepatitis B virus infection, the immune response and hepatocellular carcinoma. Ciba Found Symp1994;187:113.

96. EvansAA, O'ConnellAP, PughJC, et al.Geographic variation in viral load among hepatitis B carriers with differing risks of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev1998;7:559.

97. VillaE, BaldiniGM, PasquinelliC, et al.Risk factors for hepatocellular carcinoma in Italy. Male sex, hepatitis B virus, non‐A non‐B infection, and alcohol. Cancer1988;62:611. CrossRef

98. HadziyannisSJ. Delta antigen positive chronic liver disease in Greece: clinical aspects and natural course. Prog Clin Biol Res1983;143:209.

99. TangJR, HsuHY, LinHH, et al.Hepatitis B surface antigenemia at birth: a long‐term follow‐up study. J Pediatr1998;133:374. CrossRef

100. FarciP, NiroG. Clinical features of hepatitis D. Semin Liver Dis2012;32:228. CrossRef

101. JiJ, SunquistK, SundquistJ. A population‐based study of hepatitis D virus as a potential risk factor for hepatocellular carcinoma. J Natl Cancer Inst2012;104:790. CrossRef

102. RomeoR, Del NinnoE, RumiM, et al.A 28 year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology2009;136:1629. CrossRef

103. MionF, BoillotO, GilleD, et al.Liver transplantation for posthepatic B‐delta cirrhosis: prevention of recurrence with high‐dose anti‐HBs immunoglobulins. Transplant Proc1993;25:2638.

104. CooleyL, AyresA, BartholomeuszA, et al.Prevalence and characterization of lamivudine‐resistant hepatitis B virus mutations in HIV‐HBV co‐infected individuals. AIDS2003;17:1649. CrossRef

105. ThioCL. Hepatitis B in the human immunodeficiency virus‐infected patient: epidemiology, natural history, and treatment. Semin Liver Dis2003;23:125. CrossRef

106. ThioCL. Management of chronic hepatitis B in the HIV‐infected patient. AIDS Read2004;14:122.

107. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV‐1‐infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf Accessed May 2013.

108. SorianoV, PuotoM, PetersM, et al.Care of HIV patients with chronic hepatitis B; updated recommendations from the HIV‐Hepatitis B Virus International Panel. AIDS2008;22:1399. CrossRef

109. McMahonMA, JilekBL, BrennanTP, et al.The HBV drug entecavir – effects on HIV‐1 replication and resistance. N Engl J Med2007;356:2614. CrossRef

110. KosiL, ReibergerT, PayerBA, et al.Five‐year on‐treatment efficacy of lamivudine−, tenofovir−, and tenofovir+ emtricibatine‐based HAART in HBV‐HIV coinfected patients. J Viral Hepatol2012;19:801. CrossRef

111. CicconiP, Cozzi‐LepriA, PhillipsA, et al.Is the increased risk of liver enzyme elevation in patients co‐infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?AIDS2007;21:599. CrossRef

112. ColombariR, DhillonAP, PiazzolaE, et al.Chronic hepatitis in multiple virus infection: histopathological evaluation. Histopathology1993;22:319. CrossRef

113. FukudaR, IshimuraN, HamamotoS, et al.Co‐infection by serologically‐silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down‐regulation of type‐I interferon receptor gene expression in the liver. J Med Virol2001;63:220. CrossRef

114. KuboS, NishiguchiS, HirohashiK, et al.High prevalence of infection with hepatitis B and C viruses in patients with hepatocellular carcinoma in Japan. Hepatogastroenterology1999;46:357.

115. MimmsLT, MosleyJW, HollingerFB, et al.Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. BMJ1993;307:1095. CrossRef

116. TsaiJF, JengJE, HoMS, et al.Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer1997;76:968. CrossRef

117. ZylberbergH, LandauA, CarnotF, et al.Impact of co‐infection by hepatitis B virus and hepatitis C virus in renal transplantation. Transplant Proc1998;30:2820. CrossRef

118. CooksleyWG. Consensus statement on the role of hepatitis A vaccination in patients with chronic liver disease. J Viral Hepatol2000;7(Suppl 1):29. CrossRef

119. LiawYF, SungJJ, ChowWC, et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med2004;351:1521. CrossRef

120. LauGK, PiratvisuthT, LuoKX, et al.Peginterferon alfa‐2a, lamivudine, and the combination for HBeAg‐positive chronic hepatitis B. N Engl J Med2005;352:2682. CrossRef

121. IshakK, BaptistaA, BianchiL, et al.Histologic grading and staging of hepatitis. J Hepatol1995;22:696. CrossRef

122. BedossaP, PoynardT. An algorithm for the grading of activity in chronic hepatitis C. The Metavir Cooperative Study Group. Hepatology1996;24:289. CrossRef

123. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol2012;57:167. CrossRef

124. EddlestonA. Interferons in the treatment of chronic hepatitis B virus infection. Med Clin North Am1986;25(Suppl).

125. Di BisceglieAM. Long‐term outcome of interferon‐alpha therapy for chronic hepatitis B. J Hepatol1995;22(1 Suppl):65. CrossRef

126. MarcellinP, LauGK, BoninoF, et al.Peginterferon alfa‐2a alone, lamivudine alone, and the two in combination in patients with HBeAg‐negative chronic hepatitis B. N Engl J Med2004;351:1206. CrossRef

127. WongJB, KoffRS, TineF, et al.Cost‐effectiveness of interferon‐alpha 2b treatment for hepatitis B e antigen‐positive chronic hepatitis B. Ann Intern Med1995;122:664. CrossRef

128. KorenmanJ, BakerB, WaggonerJ, et al.Long‐term remission of chronic hepatitis B after alpha‐interferon therapy. Ann Intern Med1991;114:629. CrossRef

129. ChanHL, LeungNW, HuiAY, et al.A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon‐alpha2b and lamivudine with lamivudine alone. Ann Intern Med2005;142:240. CrossRef

130. JanssenHL, van ZonneveldM, SenturkH, et al.Pegylated interferon alfa‐2b alone or in combination with lamivudine for HBeAg‐positive chronic hepatitis B: a randomised trial. Lancet2005;365:123. CrossRef

131. RijckborstV, HansenBE, CakalogluY, et al.Early on‐treatment prediction of response to Peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology2010;52:454. CrossRef

132. SonneveldMJ, RijckborstV, BoucherCA, et al.Prediction of sustained response to peginterferon alfa‐2B for hepatitis B e antigen‐positive chronic hepatitis B using on‐treatment hepatitis B surface antigen decline. Hepatology2010;52:1251. CrossRef

133. LamperticoP, ViganoM, CheroniC, et al.IL28B polymorphisms predict interferon‐related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen‐negative patients with chronic hepatitis B. Hepatology2013;57:890. CrossRef

134. SonneveldMJ, WongVW, WotmanAM, et al.Polymorphisms at rs12979860 and rs12980275 near IL28B predict serological response to (Peg)‐interferon in HBeAg‐positive chronic hepatitis B. J Hepatol2011;54(Suppl 1):S32. CrossRef

135. KimHJ, ParkDI, ParkJH, et al.Comparison between clevudine and entecavir treatment for antiviral naïve patients with chronic hepatitis B. Liver Int2010;30:834. CrossRef

136. DienstagJL, GoldinRD, HeathcoteEJ, et al.Histological outcome during long‐term lamivudine therapy. Gastroenterology2003;124:1. CrossRef

137. DienstagJL, SchiffER, MitchellM, et al.Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology1999;30:1082. CrossRef

138. LiawYF, LeungNW, ChangTT, et al.Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology2000;119:172. CrossRef

139. LaiC‐L, YuenM‐F. Prevention of hepatitis B virus‐related hepatocellular carcinoma with antiviral therapy. Hepatology2013;57:399. CrossRef

140. HadziyannisSJ, PapatheodoridisGV, DimouE, et al.Efficacy of long‐term lamivudine monotherapy in patients with hepatitis B e antigen‐negative chronic hepatitis B. Hepatology2000;32:847. CrossRef

141. MarcellinP, ChangTT, LimSG, et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen‐positive chronic hepatitis B. N Engl J Med2003;348:808. CrossRef

142. HadziyannisSJ, TassopoulosNC, HeathcoteEJ, et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen‐negative chronic hepatitis B. N Engl J Med2003;348:800. CrossRef

143. HadziyannisS, TassopoulosN, ChangTT, et al.Two‐state modeling of virological and biochemical efficacy plus liver biopsies demonstrate efficacy of adefovir dipivoxil in HBsAg‐negative chronic hepatitis B over 4 or 5 years. J Hepatol2006;44(Suppl 2):S283. CrossRef

144. ChangTT, ShiffmanML, TongM, et al.Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B. J Hepatol2006;44(Suppl 2):S187. CrossRef

145. Borroto‐EsodaK, ArterburnS, SnowA. Final analysis of the virological outcomes and resistance during 5 years of adefovir dipivoxil monotherapy in HBeAg‐negative patients. J Hepatol2006;44(Suppl 2):S179. CrossRef

146. LeeYS, SuhDJ, LimYS, et al.Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology2006;43:1385. CrossRef

147. YeonJE, YooW, HongSP, et al.Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut2006;55:1488. CrossRef

148. RaptiI, DimouE, MitsoulaP, et al.Adding‐on versus switching‐to adefovir therapy in lamivudine‐resistant HBeAg negative chronic hepatitis B. Hepatology2007;45:266. CrossRef

149. LamperticoP, ViganoM, ManentiE, et al.Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine. Hepatology2005;42:1414. CrossRef

150. LaiCL, RosmawatiM, LaoJ, et al.Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology2002;123:1831. CrossRef

151. ChangTT, GishRG, de ManR, et al.A comparison of entecavir and lamivudine for HBeAg‐positive chronic hepatitis B. N Engl J Med2006;354:1001. CrossRef

152. ChangTT, GishRG, HadziyannisSJ, et al.A dose‐ranging study of the efficacy and tolerability of entecavir in lamivudine‐refractory chronic hepatitis B patients. Gastroenterology2005;129:1198. CrossRef

153. InnaimoSF, SeiferM, BisacchiGS, et al.Identification of BMS‐200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother1997;41:1444.

154. SeiferM, HamatakeRK, ColonnoRJ, et al.In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS‐200475 and lobucavir. Antimicrob Agents Chemother1998;42:3200.

155. LaiCL, ShouvalD, LokAS, et al.Entecavir versus lamivudine for patients with HBeAg‐negative chronic hepatitis B. N Engl J Med2006;354:1011. CrossRef

156. ChangTT, ChaoYC, KaymakogluSE, et al.Entecavir maintained virologic suppression through 3 years of treatment in antiviral‐naive HBeAg(+) patients (ETV 022/901). Hepatology2006;44(4 Suppl 1):66A.

157. ColonnoRJ, RoseRE, PokornowskiK, et al.Assessment at three years shows high barrier to resistance is maintained in entecavir‐treated nucleoside analogue naive patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology2006;44:229. CrossRef

158. YuenMF, SetoWK, FungJ, et al.Three years of continuous entecavir therapy in treatment‐naïve chronic hepatitis B patients: VIRAL suppression, viral resistance and clinical safety. Am J Gastroenterol2011;106:1264. CrossRef

159. ShermanM, YurdaydinC, SollanoJ, et al.Entecavir for treatment of lamivudine‐refractory, HBeAg‐positive chronic hepatitis B. Gastroenterology2006;130:2039. CrossRef

160. LaiCL, LeungN, TeoEK, et al.A 1‐year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen‐positive chronic hepatitis B. Gastroenterology2005;129:528. CrossRef

161. LaiCL, GaneE, HsuCW, et al.Two‐year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudine. Hepatology2006;44:222A.

162. MarcellinP, HeathcoteEJ, ButiM, et al.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med2008;359:2442. CrossRef

163. GordonSC, KrastevZ, HorbanA, et al.Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology2013;58:505. CrossRef

164. PattersonSJ, GeorgeJ, StasserSI, et al.Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut2011;60:247. CrossRef

165. van BömmelF, de ManRA, WedemeyerHL. Long‐term efficacy of tenofovir monotherapy for hepatitis B virus monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology2010;51:73. CrossRef

166. MarcellinP, GaneE, ButiM, et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5‐year open‐label follow‐up study. Lancet2013;938:468. CrossRef

167. Van RompayKK, HamiltonM, KearneyB, et al.Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques. Antimicrob Agents Chemother2005;49:2093. CrossRef

168. BenabouS, PruvostA, CoffiePA, et al.Concentrations of tenofovir and emtricitabine in breast milk of HIV‐1‐infected women in Abidjan Cote d'Ivoire, in the ANRS 12109 TEmAA study, step 2. Antimicrob Agents Chemother2011;55:1315. CrossRef

169. DienstagJL. Hepatitis B virus infection. N Engl J Med2008;359:1486. CrossRef

170. KeeffeEB, DieterichDT, HanSH, et al.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol2006;4:936. CrossRef

171. TsengTC, LiuCJ, YangHC. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology2013;57:441. CrossRef

172. SonneveldMJ, HansenBE, PiratvisuthT, et al.Response‐guided Peginterferon therapy in HBeAG‐positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology2013;58:872. CrossRef

173. SetoWK, WongDK, FungJ, et al.Reduction of hepatitis B surface antigen levels and HBsAg seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology2013;58:923. CrossRef

174. HosakaT, SuzukiF, KobayashiM, et al.Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology2013;58:98. CrossRef

175. StuyverLJ, LocarniniSA, LokA, et al.Nomenclature for antiviral‐resistant human hepatitis B virus mutations in the polymerase region. Hepatology2001;33:751. CrossRef

176. DienstagJL, PerrilloRP, SchiffER, et al.A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med1995;333:1657. CrossRef

177. LaiCL, ChingCK, TungAK, et al.Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo‐controlled trial. Hepatology1997;25:241. CrossRef

178. NevensF, MainJ, HonkoopP, et al.Lamivudine therapy for chronic hepatitis B: a six‐month randomized dose‐ranging study. Gastroenterology1997;113:1258. CrossRef

179. HonkoopP, De ManRA, NiestersHG, et al.Quantitative hepatitis B virus DNA assessment by the limiting‐dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy. J Viral Hepatol1998;5:307. CrossRef

180. BartholomewMM, JansenRW, JeffersLJ, et al.Hepatitis‐B‐virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet1997;349:20. CrossRef

181. LingR, MutimerD, AhmedM, et al.Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology1996;24:711. CrossRef

182. TipplesGA, MaMM, FischerKP, et al.Mutation in HBV RNA‐dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology1996;24:714.

183. HonkoopP, NiestersHG, De ManRA, et al.Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol1997;26:1393. CrossRef

184. ChayamaK, SuzukiY, KobayashiM, et al.Emergence and takeover of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and re‐takeover by wild type after cessation of therapy. Hepatology1998;27:1711. CrossRef

185. LiawYF, ChienRN, YehCT, et al.Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology1999;30:567. CrossRef

186. SetaT, YokosukaO, ImazekiF, et al.Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients. J Med Virol2000;60:8. CrossRef

187. BenhamouY, BochetM, ThibaultV, et al.Long‐term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus‐infected patients. Hepatology1999;30:1302. CrossRef

188. BessesenM, IvesD, CondreayL, et al.Chronic active hepatitis B exacerbations in human immunodeficiency virus‐infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis1999;28:1032. CrossRef

189. ThibaultV, BenhamouY, SeguretC, et al.Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microbiol1999;37:3013.

190. LaiCL, ChienRN, LeungNW, et al.A one‐year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med1998;339:61. CrossRef

191. DienstagJL, SchiffER, WrightTL, et al.Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med1999;341:1256. CrossRef

192. TassopoulosNC, VolpesR, PastoreG, et al.Efficacy of lamivudine in patients with hepatitis B e antigen‐negative/hepatitis B virus DNA‐positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology1999;29:889. CrossRef

193. TisdaleM, KempSD, ParryNR, et al.Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′‐thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A1993;90:5653. CrossRef

194. BartholomeuszA, GroenenLC, LocarniniSA. Clinical experience with famciclovir against hepatitis B virus and the development of resistance. Intervirology1997;40:337. CrossRef

195. BartholomeuszA, SchinaziR, LocarniniS. Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease. Viral Hepat Rev1998;4:167.

196. OgataN, FujiiK, TakigawaS, et al.Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol1999;59:270. CrossRef

197. DelaneyWE, YangH, WestlandCE, et al.The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol2003;77:11833. CrossRef

198. HadziyannisSJ, TassopoulosNC, HeathcoteEJ, et al.Long‐term therapy with adefovir dipivoxil for HBeAg‐negative chronic hepatitis B. N Engl J Med2005;352:2673. CrossRef

199. LocarniniS, QiX, ArterburnS, et al.Incidence and predictors of emergence of HBV mutations associated with ADV resistance during 4 years of ADV therapy for patients with chronic HBV. J Hepatol2005;42(Suppl 2):17.

200. BartholomeuszA, TehanBG, ChalmersDK. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther2004;9:149.

201. SheldonJ, CaminoN, RodesB, et al.Selection of hepatitis B virus polymerase mutations in HIV‐coinfected patients treated with tenofovir. Antivir Ther2005;10:727.

202. TenneyDJ, LevineSM, RoseRE, et al.Clinical emergence of entecavir‐resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother2004;48:3498. CrossRef

203. BrechotC, NalpasB, FeitelsonMA. Interactions between alcohol and hepatitis viruses in the liver. Clin Lab Med1996;16:273.

204. SamuelD, ZignegoAL, ReynesM, et al.Long‐term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology1995;21:333. CrossRef

205. PerrilloR, RakelaJ, DienstagJ, et al.Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology1999;29:1581. CrossRef

206. CholongitasE, VasiliadisT, AntoniadisN, et al.Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis2012;14:479. CrossRef

207. UemotoS, InomataY, SannomiyaA, et al.Posttransplant hepatitis B infection in liver transplantation with hepatitis B core antibody‐positive donors. Transplant Proc1998;30:134. CrossRef

208. WachsME, AmendWJ, AscherNL, et al.The risk of transmission of hepatitis B from HBsAg(−), HBcAb(+), HBIgM(−) organ donors. Transplantation1995;59:230. CrossRef

209. ChenPM, ChiouTJ, FanFS, et al.Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation. Transplantation1999;67:1425. CrossRef

210. FornaironS, PolS, LegendreC, et al.The long‐term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation1996;62:297. CrossRef

211. WedemeyerH, PethigK, WagnerD, et al.Long‐term outcome of chronic hepatitis B in heart transplant recipients. Liver Transpl Surg1996;2:132. CrossRef

212. FabiaR, LevyMF, CrippinJ, et al.De novo hepatitis B infection after liver transplantation: source of disease, incidence, and impact. Liver Transpl Surg1998;4:119. CrossRef

213. ChenG, LinW, ShenF, et al.Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol2006;101:1797. CrossRef

214. LocarniniS. Molecular virology of hepatitis B virus. Semin Liver Dis2004;24(Suppl 1):3. CrossRef